Skip to main content
Descovy approved as 2nd PrEP drug for HIV, with exclusions
10/4/2019

Gilead Sciences' Descovy, or emtricitabine and tenofovir alafenamide, has gained FDA approval as the second option for pre-exposure HIV prophylaxis. The approval indicates the drug can be used to prevent the disease in transgender women and HIV-negative men who have sex with men but does not cover cisgender women.

Full Story: